Description
SARS-CoV-2 Spike D614G mutant Cell Line stable expresses SARS-CoV-2 Spike Glycoprotein encoding a D614G mutation. Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, such as respiratory, enteric, renal, and neurological diseases. A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalent form in the global pandemic. D614G mutation shows potentially higher viral loads in COVID-19 patients (Ref. 1).
SARS-CoV-2 uses its spike glycoprotein (S), a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry. It uses human ACE2 to enter cells, correlating with the efficient spread of SARS-CoV-2 among humans. S comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and also fusion of the viral and cellular membranes (S2 subunit). SARS-CoV-2 Spike Glycoprotein Cell Line allows the study of SARS-CoV-2 spike/ ACE2 interaction in cell-based assays.
SARS-CoV-2 Spike D614G mutant Cell Line, developed stably transfecting HEK293 cell line with a SARS-CoV-2 Spike D614G mutant expression plasmid, provides consistent levels of expression of human SARS-CoV-2 Spike D614G mutant in cells surface. Each vial of cells contains more than 3 million viable cells stably expressing SARS-CoV-2 Spike D614G mutant with hygromycin resistance gene.
SARS-CoV-2 Spike D614G mutant Cell line is ready to use in cell-based assay applications. This cell line also allows to establish in vitro models for High Throughput and High Content Screening.
Reviews
There are no reviews yet.